ATC Group: J04AK02 Ethambutol

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of J04AK02 in the ATC hierarchy

Level Code Title
1 J Antiinfectives for systemic use
2 J04 Antimycobacterials
3 J04A Drugs for treatment of tuberculosis
4 J04AK Other drugs for treatment of tuberculosis
5 J04AK02 Ethambutol

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 1.2 g
PAREN - Parenteral 1.2 g

Active ingredients in J04AK02

Active Ingredient Description
Ethambutol

Ethambutol is bacteriostatic. It is effective against Mycobacterium tuberculosi and M.bovis with an MIC of 0.5–8ยตg per ml. The exact mechanism of action is unknown. While it has activity against some atypical mycobacteria including M.Kansasii, activity against other micro-organisms has not yet been reported.

Related product monographs

Title Information Source Document Type  
ETIBI Tablet Health Products and Food Branch (CA) MPI, CA: SPM
MYAMBUTOL Film-coated tablet FDA, National Drug Code (US) MPI, US: SPL/Old

Medicines in this ATC group

United States (US)

Austria (AT)

Canada (CA)

Estonia (EE)

France (FR)

Hong Kong (HK)

Japan (JP)

Malta (MT)

Mexico (MX)

Netherlands (NL)

Singapore (SG)

South Africa (ZA)

Spain (ES)

Turkey (TR)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.